Cargando…
PDE4 inhibitors as potential therapeutic agents in the treatment of COPD-focus on roflumilast
Chronic obstructive pulmonary disease is characterized by a rapid decline in lung function due to small airway fibrosis, mucus hypersecretion and emphysema. The major causative factor for COPD is cigarette smoking that drives an inflammatory process that gives rise to leukocyte recruitment, imbalanc...
Autores principales: | Boswell-Smith, Victoria, Spina, Domenico |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2695611/ https://www.ncbi.nlm.nih.gov/pubmed/18044684 |
Ejemplares similares
-
The Role of the Pharmacist in Optimizing Outcomes With Roflumilast, a PDE4 Inhibitor for the Treatment of COPD
por: Williams, Dennis
Publicado: (2020) -
Reduction of exacerbations by the PDE4 inhibitor roflumilast - the importance of defining different subsets of patients with COPD
por: Rennard, Stephen I, et al.
Publicado: (2011) -
New therapeutic options in the management of COPD – focus on roflumilast
por: Antoniu, Sabina Antonela
Publicado: (2011) -
Roflumilast: first phosphodiesterase 4 inhibitor approved for treatment of COPD
por: Giembycz, Mark A, et al.
Publicado: (2010) -
Scope of adjuvant therapy using roflumilast, a PDE-4 inhibitor against COVID-19
por: S, Sugin Lal Jabaris, et al.
Publicado: (2021)